Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...

A new experimental drug is showing potential in treating prostate cancer and possibly other forms of the disease. A new immunotherapy drug used in a prostate cancer clinical trial is showing early ...

Add Yahoo as a preferred source to see more of our stories on Google. Hormonal changes in a man's aging body can cause the prostate to grow—resulting in urinary problems since the gland is wrapped ...

Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...